Unity Biotechnology Stock Alpha and Beta Analysis
| UBX Stock | USD 1.30 0.53 28.96% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Unity Biotechnology. It also helps investors analyze the systematic and unsystematic risks associated with investing in Unity Biotechnology over a specified time horizon. Remember, high Unity Biotechnology's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Unity Biotechnology's market risk premium analysis include:
Beta (0.89) | Alpha 0.73 | Risk 10.66 | Sharpe Ratio 0.0876 | Expected Return 0.93 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Unity |
Unity Biotechnology Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Unity Biotechnology market risk premium is the additional return an investor will receive from holding Unity Biotechnology long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Unity Biotechnology. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Unity Biotechnology's performance over market.| α | 0.73 | β | -0.89 |
Unity Biotechnology expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Unity Biotechnology's Buy-and-hold return. Our buy-and-hold chart shows how Unity Biotechnology performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Unity Biotechnology Market Price Analysis
Market price analysis indicators help investors to evaluate how Unity Biotechnology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Unity Biotechnology shares will generate the highest return on investment. By understating and applying Unity Biotechnology stock market price indicators, traders can identify Unity Biotechnology position entry and exit signals to maximize returns.
Unity Biotechnology Return and Market Media
The median price of Unity Biotechnology for the period between Wed, Dec 25, 2024 and Tue, Mar 25, 2025 is 1.76 with a coefficient of variation of 24.26. The daily time series for the period is distributed with a sample standard deviation of 0.42, arithmetic mean of 1.72, and mean deviation of 0.31. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 324 shares by Lynne Sullivan of Unity Biotechnology at 1.4 subject to Rule 16b-3 | 12/27/2024 |
2 | Insider Trading | 12/31/2024 |
3 | Acquisition by Grossi Federico of 150000 shares of Unity Biotechnology at 1.78 subject to Rule 16b-3 | 01/06/2025 |
4 | Acquisition by Leonard Keith R of 25000 shares of Unity Biotechnology subject to Rule 16b-3 | 01/17/2025 |
5 | Acquisition by Anirvan Ghosh of 450000 shares of Unity Biotechnology at 2.09 subject to Rule 16b-3 | 01/22/2025 |
6 | Disposition of 642 shares by Anirvan Ghosh of Unity Biotechnology at 2.23 subject to Rule 16b-3 | 02/04/2025 |
7 | HC Wainwright Has Strong Estimate for UBX FY2025 Earnings - Defense World | 03/12/2025 |
8 | Acquisition by Nguyen Alexander Hieu of 150000 shares of Unity Biotechnology at 2.09 subject to Rule 16b-3 | 03/14/2025 |
9 | UNITY Biotechnology Shares Drop 33 percent After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema | 03/24/2025 |
About Unity Biotechnology Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Unity or other stocks. Alpha measures the amount that position in Unity Biotechnology has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2024 | 2025 (projected) | |
| Interest Debt Per Share | 5.36 | 1.17 | 1.11 |
| Revenue Per Share | 0.0249 | 0.0286 | 0.0272 |
Unity Biotechnology Upcoming Company Events
As portrayed in its financial statements, the presentation of Unity Biotechnology's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Unity Biotechnology's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Unity Biotechnology's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Unity Biotechnology. Please utilize our Beneish M Score to check the likelihood of Unity Biotechnology's management manipulating its earnings.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Unity Biotechnology
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Unity Stock Analysis
When running Unity Biotechnology's price analysis, check to measure Unity Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unity Biotechnology is operating at the current time. Most of Unity Biotechnology's value examination focuses on studying past and present price action to predict the probability of Unity Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unity Biotechnology's price. Additionally, you may evaluate how the addition of Unity Biotechnology to your portfolios can decrease your overall portfolio volatility.